about
Evolutionary history and attenuation of myxoma virus on two continentsCytokine synergy: an underappreciated contributor to innate anti-viral immunityOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesStructure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastomaRIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophagesOncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivoProduction of Myxoma virus gateway entry and expression libraries and validation of viral protein expressionOncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusInfection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta.Myxoma virus and the Leporipoxviruses: an evolutionary paradigm.Oncolytic Poxviruses.Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.M135R is a novel cell surface virulence factor of myxoma virusOncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.Genetic characterization of interleukins (IL-1α, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12A, IL-12B, IL-15 and IL-18) with relevant biological roles in lagomorphs.An overview of the lagomorph immune system and its genetic diversity.Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbitsVariation in host susceptibility and infectiousness generated by co-infection: the myxoma-Trichostrongylus retortaeformis case in wild rabbits.Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway.Oncolytic myxoma virus: the path to clinicGenome scale evolution of myxoma virus reveals host-pathogen adaptation and rapid geographic spread.The current status and future directions of myxoma virus, a master in immune evasion.Viral serpin therapeutics from concept to clinic.Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.Myxoma and vaccinia viruses bind differentially to human leukocytes.Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.Myxoma virus: propagation, purification, quantification, and storageMyxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.Systemic virotherapy for multiple myeloma.Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria.Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak.Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized.The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts.Atypical myxomatosis--virus isolation, experimental infection of rabbits and restriction endonuclease analysis of the isolate.Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier.
P2860
Q21558784-A31666CE-9AA5-41BE-A3C1-3B54A671132AQ26852421-5C14092C-673E-444A-BF9A-6EDD2C99AC0EQ27007519-21FFB841-3D73-4497-83D6-CEB6807A3502Q27644227-4BF2C847-3A62-441B-B6E3-FFE69DACAE6CQ30493691-3E16944E-A355-4231-8A15-66A607BF0C74Q30845041-359A91AF-B3BF-48E0-BDEA-330D97EDAD72Q33750535-5C56CE6E-8BBA-4632-B796-34CBE7E38EFBQ33780691-5DD39D7A-D821-4D33-8A08-49494A3FF34AQ33888269-BD55A157-56D8-467E-A955-DEB0BE13B2EEQ33895494-59C011CE-C593-4752-AFB8-3FE416A1763BQ34574890-9BD6AD7D-54F0-4BA1-9FE9-B79A5585E0C5Q35216380-DAD555E9-04D8-4EE3-8571-51E23F872BB1Q35223463-31EC1AB0-BE75-40F8-AC6B-22DC48BA022DQ35232793-579163B0-0AD9-46FF-9925-8E8AAF00B563Q35234349-F0C3BB02-6452-45C9-B997-85058D2A15EFQ35234447-1CF8EFFC-AA25-4E43-95F3-07C416676A3CQ35634308-F88D47DA-DE4B-4EB8-BB26-F10A46E22EBBQ35635226-6A337AEE-BDF1-4159-AC52-B8B7C9D4EF1CQ35784301-2A27224A-0139-401E-ACBE-440486D1624EQ35785529-D4F07555-AB5C-45BA-B6F9-7E83DE5AE3D7Q36315458-46534047-3495-4584-B175-76A5E908F5F9Q36662611-2583C35E-E725-48BE-83EF-AA3D7D59586CQ36922264-E8388816-4815-405B-8DE8-F90F66C7E354Q37003173-4AB581A9-4C7A-4B79-8165-BADCD79A110AQ37126088-CD103C94-F4C6-45B6-BF50-6D22525B2B5FQ37336515-12442BF6-461D-46E3-85E5-F2B8C3AB7371Q37887080-14768FD4-6EBB-4505-B9FE-2F9EB856DD12Q37891258-BDCCA419-5E68-4A1D-8272-2F62F8B44BBAQ38961205-B98DF1B5-ACBF-4A32-B99C-329D84C1410DQ39198482-018E27EB-7EA4-4F6B-8EDB-DE35050D3804Q39292187-01683882-5DD7-44D8-939F-C1D57551B561Q39707862-DB7E7DC8-2D76-4765-A1DA-882BD510AA3AQ39995833-B78F5AF8-5E92-4D16-8DBB-1351FB928A40Q40087770-6DB59013-F4C9-497F-82EA-4DBCB460425FQ40329192-E21C5104-EB15-4767-A0F3-87F3A961B133Q40545931-1897604B-0636-4581-9866-273D1401F23FQ41988706-E0D930BD-0A7F-4D52-ABD5-30AA829907CDQ43215263-10376262-239E-4E3F-9944-BFF8AFA963D3Q43441279-F409369E-BF7D-496C-B0C9-4F466F538C2DQ45560504-16B9DA33-D045-4879-8944-909A98799B99
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immune responses to myxoma virus.
@ast
Immune responses to myxoma virus.
@en
Immune responses to myxoma virus.
@nl
type
label
Immune responses to myxoma virus.
@ast
Immune responses to myxoma virus.
@en
Immune responses to myxoma virus.
@nl
prefLabel
Immune responses to myxoma virus.
@ast
Immune responses to myxoma virus.
@en
Immune responses to myxoma virus.
@nl
P1433
P1476
Immune responses to myxoma virus.
@en
P2093
Peter Kerr
P304
P356
10.1089/08828240260066198
P577
2002-01-01T00:00:00Z